Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2025 |
Sep. 30, 2025 |
Sep. 30, 2024 |
Aug. 12, 2024 |
|
| Nature of Operations and Basis of Presentation [Line Items] | ||||
| Total shares outstanding (in Shares) | 71,552,402 | 71,552,402 | ||
| Net amount | $ 2,753,795 | $ 2,753,795 | ||
| Additional paid in capital | 127,979,246 | 108,897,836 | $ 85,411,771 | |
| Cash | 7,295,451 | 3,924,908 | ||
| Transaction costs | $ 2,358,780 | 2,358,780 | ||
| Cash contributions | 3,827,944 | |||
| Capital receivables | 33,180,961 | |||
| Additional payable | $ 3,800,111 | |||
| Citius Pharma [Member] | ||||
| Nature of Operations and Basis of Presentation [Line Items] | ||||
| Ownership percentage | 78.00% | 79.00% | 92.00% | |
| Cash contributions | $ 3,827,944 | $ 3,827,944 | ||
| Capital receivables | 33,180,961 | |||
| Additional payable | 3,800,111 | 3,800,111 | ||
| TenX [Member] | ||||
| Nature of Operations and Basis of Presentation [Line Items] | ||||
| Additional paid in capital | 395,015 | 395,015 | ||
| Cash | 163,500 | 163,500 | ||
| Liabilities | $ 559,015 | $ 559,015 | ||
| X | ||||||||||
- Definition Additional paid in capital receivables. No definition available.
|
| X | ||||||||||
- Definition Related transaction costs. No definition available.
|
| X | ||||||||||
- Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of excess stock held by shareholders. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received by a corporation from a shareholder during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from a borrowing supported by a written promise to pay an obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|